ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Mainz Biomed B.V. (MYNZ) stock declined over -0.89%, trading at $3.34 on NASDAQ, down from the previous close of $3.37. The stock opened at $3.26, fluctuating between $3.21 and $3.54 in the recent session.
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
Employees | 65 |
Beta | 0.53 |
Sales or Revenue | $895.48K |
5Y Sales Change% | 1.294% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Medical - Diagnostics & Research |